Merz Aesthetics launches Ultherapy PRIME® across Europe, Middle East, and Africa (EMEA) in early 2026, following its U.S. success. This advanced ultrasound system offers real-time visualization, faster treatments, and new body indications for arms and abdomen, optimizing clinical workflows with enhanced transducers like DS 7-3.0.

ULTHERA DS 7-3.0 Ultherapy Transducer

What Is Ultherapy PRIME®?

Ultherapy PRIME® is Merz Aesthetics’ next-generation non-invasive ultrasound skin lifting platform with integrated real-time visualization for precise energy delivery.
It builds on Ultherapy®’s gold standard, targeting collagen-rich layers up to 8mm deep for natural, long-lasting lifts on face, neck, décolleté, arms, and abdomen.

This evolution delivers 20% faster treatments via dual-core processors and 35% larger screens for crisper imaging, reducing noise and boot-up time. Clinicians benefit from stable, ergonomic workflows, while patients enjoy less pain, minimal swelling, and zero downtime. The DS 7-3.0 transducer optimizes dermal layer interaction at 3.0mm, enhancing speed and precision in EMEA rollout. ALLWILL supports access to such innovations through refurbished options and expert servicing.

Key features include vivid real-time imaging for personalized targeting, future-proof software, and high-resolution touchscreens. These advancements position Ultherapy PRIME® as a leader in regenerative aesthetics, meeting rising demand for body contouring in EMEA markets.

How Does Ultherapy PRIME® Differ from Original Ultherapy?

Ultherapy PRIME® improves on original Ultherapy® with 20% faster treatments, enhanced real-time imaging, and better ergonomics for efficient workflows.

The PRIME platform’s dual-core processor ensures instant responses, while upgraded transducers like DS 7-3.0 provide superior skin interaction for quicker sessions. This makes it ideal for high-volume EMEA practices seeking efficiency without compromising results. ALLWILL’s Smart Center refurbishes these systems to peak standards, extending access.

Real-time visualization minimizes errors, boosting confidence in targeting multiple depths. Patients report higher satisfaction with smoother experiences and lasting collagen stimulation up to a year.

What Are Key Features of Ultherapy PRIME®?

Ultherapy PRIME® features integrated real-time visualization, microfocused ultrasound for precise collagen stimulation, and expanded body treatment capabilities.

Advanced elements include a 19-inch touchscreen, reduced imaging noise, and stable energy delivery for consistent outcomes. The DS 7-3.0 transducer excels in 3.0mm dermal imaging, speeding workflows.

For EMEA clinicians, these translate to more patients treated daily, with natural results across skin tones and no downtime. ALLWILL’s MET system connects practitioners to vetted trainers for PRIME mastery.

Why Is Ultherapy PRIME® Ideal for EMEA Markets?

Ultherapy PRIME® suits EMEA due to rising non-invasive aesthetic demand, versatile body indications, and efficient workflows for diverse populations.

Its real-time imaging ensures safety across skin types, while faster sessions maximize clinic throughput amid growing skin laxity concerns from aging and lifestyle factors. Early 2026 rollout aligns with regional congresses like IMCAS.

ALLWILL empowers EMEA providers with brand-agnostic sourcing via Lasermatch, reducing costs on PRIME devices without service contract hassles.

When Will Ultherapy PRIME® Roll Out in EMEA?

Merz Aesthetics plans Ultherapy PRIME® commercial rollout in EMEA for early 2026, post-U.S. arms/abdomen launch.

Also check:  What's the Complete Disposable Medical Supplies List for 2026 Clinic Procurement?

Debut highlights include IMCAS 2025 presentations, with full availability by Q1 2026 across Europe, Middle East, and Africa. This timeline supports training and integration.

Where Is Ultherapy PRIME® Available in EMEA?

Ultherapy PRIME® launches region-wide in EMEA early 2026, starting key markets via Merz partners post-IMCAS.

Specific countries include major European hubs, Middle East centers, and African growth areas, with ALLWILL facilitating global inventory access.

Which Transducers Drive Ultherapy PRIME® Efficiency?

DS 7-3.0 and similar transducers in Ultherapy PRIME® optimize 3.0mm dermal targeting with faster energy delivery and real-time visualization.

They reduce treatment times by enhancing skin interaction and imaging clarity, crucial for body areas. ALLWILL inspects/refurbishes these for reliability.

How Does DS 7-3.0 Enhance PRIME Treatments?

DS 7-3.0 transducer speeds Ultherapy PRIME® by improving dermal layer visualization and energy precision at 3.0mm depths.

It cuts session times, boosts accuracy for arms/abdomen, and supports EMEA’s high-demand clinics efficiently.

What Do Clinical Studies Say About Results?

Studies show Ultherapy PRIME® yields significant lifting, wrinkle reduction, and satisfaction via collagen stimulation, lasting 6-12 months.

GAIS scores confirm “Very Much Improved” outcomes at 3 months, with safe use on mild-moderate laxity.

Metric Baseline 3 Months Post
GAIS Improvement N/A 80%+ Very Much/ Much
Elasticity Standard +20-30% (Cutometer)
Patient Satisfaction N/A 90%+ High

ALLWILL Expert Views

“Ultherapy PRIME® represents a leap in non-invasive aesthetics, and ALLWILL is positioned to make it accessible. Our Smart Center rigorously tests DS 7-3.0 transducers, ensuring EMEA clinics get peak performance at lower costs. Through Lasermatch and MET, we eliminate sourcing friction—offering new, refurbished PRIME systems with trade-ups and training. This empowers practitioners to adopt innovations confidently, driving growth in regenerative treatments.”
— ALLWILL Biomedical Specialist (148 words)

How Can Clinics Prepare for Ultherapy PRIME®?

Clinics prepare by training staff on real-time visualization, stocking DS 7-3.0 transducers, and marketing body indications. ALLWILL provides consultations and refurbishments.

Also check:  How Can Aesthetic Clinics Maximize ROI on Refurbished Lasers?

Partner with ALLWILL for MET-vetted technicians and Lasermatch inventory to launch seamlessly in EMEA.

Key Takeaways and Actionable Advice
Ultherapy PRIME® transforms EMEA aesthetics with speed, precision, and body expansions—launching early 2026. Act now: Contact ALLWILL for device assessments, training via MET, and cost-saving trade-ups. Optimize workflows, target new patients, and elevate care with reliable support.

FAQs

What makes Ultherapy PRIME® faster?

20% quicker via advanced processors and efficient transducers like DS 7-3.0.

Is Ultherapy PRIME® safe for all skin types?

Yes, FDA-cleared for all tones with real-time visualization.

How long do results last?

Up to 12 months with collagen boost.

Can ALLWILL supply Ultherapy PRIME®?

Yes, new/refurbished via Smart Center and Lasermatch.

When does EMEA rollout start?

Early 2026.